Sharon Shacham

12.4k citations

221 papers · 5.8k indexed · h-index 46

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Molecular Biology top 1%
- Nuclear Structure and Function
- RNA Research and Splicing
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Receptor Mechanisms and Signaling

Papers in

Hematology 46
- Acute Myeloid Leukemia Research 25
- Multiple Myeloma Research and Treatments 22
Molecular Biology 173
- Nuclear Structure and Function 131
- RNA Research and Splicing 24
- Protein Degradation and Inhibitors 15

Co-authors: Michael Kauffman Yosef Landesman Dilara McCauley Erkan Baloglu William Senapedis Zvi Naor Dagan Harris Yael Marantz
Journals: Blood (45 papers)Journal of Clinical Oncology (33 papers)Cancer Research (32 papers)Oncotarget (14 papers)Annals of Oncology (8 papers)
Partner nations: United States Canada Denmark

In The Last Decade

Sharon Shacham

216 papers receiving 5.7k citations

Peers

Countries citing papers authored by Sharon Shacham

Since Specialization

Citations

This map shows the geographic impact of Sharon Shacham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Shacham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Shacham more than expected).

Fields of papers citing papers by Sharon Shacham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Shacham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Shacham. The network helps show where Sharon Shacham may publish in the future.

Co-authors

The 25 scholars most cited alongside Sharon Shacham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sharon Shacham Line = papers co-authored together Sharon Shacham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML Blood Advances ·Giulia Pianigiani, Andrea Gagliardi, Federica Mezzasoma, Francesca Rocchio, Valentina Tini, Barbara Bigerna, Paolo Sportoletti, Simona Caruso, Andrea Marra, Sara Peruzzi, Eleonora Petito, Giulio Spinozzi, Sharon Shacham, Yosef Landesman, Concetta Quintarelli, Paolo Gresele, Franco Locatelli, Maria Paola Martelli, Brunangelo Falini, Lorenzo Brunetti	2022	22
2	Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma Future Oncology ·Mrinal M. Gounder, Albiruni R. Abdul Razak, Adrienne M. Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martín‐Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Richard F. Riedel, Steven Attia	2021	13
3	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB Molecular Cancer Therapeutics ·Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, Y. Lynn Wang	2018	36
4	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma Blood ·John Kuruvilla, Michael R. Savona, Rachid Baz, Morten Mau‐Sørensen, Nashat Gabrail, Ramiro Garzon, Richard M. Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian W. Flinn, Meagan A. Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez	2017	112
5	XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB Blood ·Y. Lynn Wang, Mei Ming, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu	2017	1
6	A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma Blood ·Darrell White, Nizar J. Bahlis, Christopher P. Venner, Gary J. Schiller, Cristina Gasparetto, Heather J. Sutherland, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, William Bensinger, Brea Lipe, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Richard LeBlanc	2017	4
7	Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM) Blood ·Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Gary J. Schiller, Richard LeBlanc, William Bensinger, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Christine I. Chen	2017	0
8	Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure Blood ·Christine I. Chen, Heather J. Sutherland, Rami Kotb, Michaël Sébag, Darrell White, William Bensinger, Cristina Gasparetto, Richard LeBlanc, Christopher P. Venner, Suzanne Lentzsch, Gary J. Schiller, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Nizar J. Bahlis	2017	3
9	A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs) Blood ·Cristina Gasparetto, Suzanne Lentzsch, Gary J. Schiller, William Bensinger, Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Rami Kotb, Christopher P. Venner, Richard LeBlanc, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Brea Lipe	2017	2
10	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma Molecular Cancer Therapeutics ·Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2016	74
11	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia Clinical Cancer Research ·Thomas Vercruysse, Jolien De Bie, Jasper E. Neggers, Maarten Jacquemyn, Els Vanstreels, Jonathan L. Schmid‐Burgk, Veit Hornung, Erkan Baloglu, Yosef Landesman, William Senapedis, Sharon Shacham, Antonis Dagklis, Jan Cools, Dirk Daelemans	2016	53
12	XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus Clinical Cancer Research ·Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, Xiaomei Meng, Tzung-Huei Lai, Betina McNeil, Bhavana Bhatnagar, Sharon Shacham, Michael Kauffman, Adrienne M. Dorrance, William Blum, Deepa Sampath, Yosef Landesman, Ramiro Garzon	2016	67
13	Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection PLoS ONE ·Olivia Perwitasari, Scott K. Johnson, Xiuzhen Yan, Emery T. Register, Jackelyn Crabtree, Jon D. Gabbard, Elizabeth W. Howerth, Sharon Shacham, Robert Carlson, Sharon Tamir, Ralph A. Tripp	2016	26
14	Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor Molecular Cancer Therapeutics ·Shaun Rosebeck, Mattina M. Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P. Maxwell, Stephanie J. Kraftson, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak	2015	40
15	XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer Clinical Cancer Research ·Isabel Ferreiro-Neira, Nancy E. Torres, Lukas F. Liesenfeld, Carlos H.F. Chan, Tristan Penson, Yosef Landesman, William Senapedis, Sharon Shacham, Theodore S. Hong, James C. Cusack	2015	36
16	XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Yan Cheng, Michael P. Holloway, Kevin T. Nguyen, Dilara McCauley, Yosef Landesman, Michael Kauffman, Sharon Shacham, Rachel A. Altura	2014	83
17	KCP-330-005/SIGN: A phase II, open-label study of efficacy and safety of the selective inhibitor of nuclear export (SINE) KPT-330 (SELINEXOR) in patients with advanced gynaecologic malignancies International Journal of Gynecological Cancer ·Ignace Vergote, Bente Lund, Z. Ujmajuridze, Hanne Havsteen, Tami Rashal, John S. McCartney, Michael Kauffman, Sharon Shacham, Mansoor Raza Mirza	2014	2
18	CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma Molecular Cancer Therapeutics ·Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean‐Richard Saint‐Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack	2013	57
19	Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells Leukemia ·Julia Etchin, Qingxiang Sun, Alex Kentsis, Alicia Farmer, Zhong-Zhe Zhang, Takaomi Sanda, Marc R. Mansour, Carles Barceló, Dilara McCauley, Michael Kauffman, Sharon Shacham, Amanda L. Christie, Andrew L. Kung, Scott J. Rodig, Yuh Min Chook, A. Thomas Look	2012	145
20	G protein-coupled receptors: In silico drug discovery in 3D Proceedings of the National Academy of Sciences ·Oren M. Becker, Yael Marantz, Sharon Shacham, Boaz Inbal, Alexander Heifetz, Ori Kalid, Shay Bar‐Haim, Dora Toledo Warshaviak, Merav Fichman, Silvia Noiman	2004	110

About Sharon Shacham

Sharon Shacham is a scholar working on Hematology, Molecular Biology, Oncology, Cancer Research and Genetics, having authored 221 papers that have together received 5.8k indexed citations. Recurring topics across this work include Nuclear Structure and Function (131 papers), Cancer-related Molecular Pathways (37 papers), Acute Myeloid Leukemia Research (25 papers), RNA Research and Splicing (24 papers), Multiple Myeloma Research and Treatments (22 papers), Cancer, Lipids, and Metabolism (20 papers), Protein Degradation and Inhibitors (15 papers) and Lymphoma Diagnosis and Treatment (11 papers). The work is most often cited by research in Hematology (1.3k citations), Molecular Biology (4.4k citations), Oncology (1.4k citations), Genetics (419 citations) and Reproductive Medicine (224 citations). Sharon Shacham has collaborated with scholars based in United States, Canada and Denmark. Frequent co-authors include Michael Kauffman, Yosef Landesman, Dilara McCauley, Erkan Baloglu, William Senapedis, Zvi Naor, Dagan Harris, Yael Marantz, Silvia Noiman and Oren M. Becker. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Oncotarget and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact